Welcome to our dedicated page for Aptevo Therapeutics news (Ticker: APVO), a resource for investors and traders seeking the latest updates and insights on Aptevo Therapeutics stock.
Aptevo Therapeutics Inc. (NASDAQ: APVO) is a clinical-stage biotechnology company advancing novel bispecific antibody therapies for cancer treatment. This news hub provides investors and industry professionals with timely updates on APVO's clinical developments, platform innovations, and strategic milestones.
Our curated collection features official press releases and verified news about the company's ADAPTIR platform progress, clinical trial results for candidates like mipletamig in AML, and regulatory updates. Users will find updates on financial filings, research collaborations, and therapeutic pipeline expansions across hematologic malignancies and solid tumors.
This resource serves as a centralized reference for tracking APVO's progress in developing targeted immunotherapies designed to improve treatment safety and efficacy. Content is organized chronologically with clear sourcing to ensure reliable tracking of the company's scientific advancements and corporate developments.
Bookmark this page for streamlined access to APVO's latest announcements, including trial initiations, data presentations at medical conferences, and partnership disclosures. Check regularly for updates on how the company's modular protein engineering approaches aim to address unmet needs in oncology care.
Aptevo Therapeutics reported significant 2022 milestones and financial results, achieving a net income of $8.0 million ($1.57 per share) compared to a net loss of $28.5 million in 2021. The company announced progress in clinical trials for APVO436 in Acute Myeloid Leukemia (AML), which demonstrated substantial clinical activity and a favorable safety profile. The Phase 2 trial for APVO436 is set for late 2023. Additionally, ALG.APV-527, for solid tumors, began patient dosing in February 2023. Aptevo also filed a provisional patent for APVO711 targeting various solid malignancies. As of December 31, 2022, cash and equivalents totaled $22.6 million.
Aptevo Therapeutics (NASDAQ:APVO) announced the completion of a transaction that raised $9.6 million in non-dilutive funding by selling future IXINITY payments and milestones to XOMA Corporation. The company plans to use part of the proceeds to fully repay its debt, leaving it with approximately $26 million in cash and a debt-free status. Additional potential milestones related to IXINITY could yield up to $5.8 million through regulatory approvals and sales performance. This move extends Aptevo's cash runway beyond 12 months and reinforces its commitment to shareholders amid challenging market conditions.
Aptevo Therapeutics (NASDAQ:APVO) announced the initiation of a Phase 1 trial for ALG.APV-527, aimed at treating solid tumors that express the 5T4 antigen. The dosing of the first patient marks a significant milestone in Apptevo's strategic expansion into solid tumor therapies, complementing its work in hematological cancers. The trial involves multiple cohorts and will assess safety, tolerability, and preliminary efficacy at up to 10 U.S. sites. Preclinical studies suggest a promising safety profile and potential antitumor activity, with preliminary results expected later in 2023.
Aptevo Therapeutics has announced the filing of a provisional patent for APVO711, a bispecific antibody aimed at treating solid tumors like melanoma and lung carcinoma. This innovative candidate, based on their proprietary ADAPTIR platform, engages PD-L1 and CD40 to potentially enhance T cell activation while maintaining a favorable safety profile. Pre-clinical studies are set to begin this year, expanding Aptevo's oncology portfolio to five candidates. CEO Marvin White emphasized the promising efficacy of their existing candidate, APVO436, suggesting APVO711 could yield similar results.
FAQ
What is the current stock price of Aptevo Therapeutics (APVO)?
What is the market cap of Aptevo Therapeutics (APVO)?
